Quick Answer
Larimar Therapeutics, Inc. reported Operating Income Loss of -$172.50 million for the year ending 2025.
- Larimar Therapeutics, Inc. showed a decrease of -89.8% in Operating Income Loss from 2024 to 2025.
- This data is from Larimar Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 14 years of available data (2012 to 2025), Larimar Therapeutics, Inc.'s Operating Income Loss has declined by 1,150.8%.
- Historical annual values: Fiscal year 2025: -$172.50 million | Fiscal year 2024: -$90.89 million | Fiscal year 2023: -$41.76 million | Fiscal year 2022: -$36.53 million | Fiscal year 2021: -$50.47 million | Fiscal year 2020: -$42.80 million | Fiscal year 2019: -$23.21 million | Fiscal year 2018: -$61.12 million | Fiscal year 2017: -$53.00 million | Fiscal year 2016: -$58.23 million | Fiscal year 2015: -$73.81 million | Fiscal year 2014: -$35.53 million | Fiscal year 2013: -$13.78 million | Fiscal year 2012: -$13.79 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: